美国宇航局向RedWire奖励400万美元以推进微重力药物开发

2026-03-11 19:25

Redwire (RDW) Wednesday announced that NASA has awarded the company an additional $4 million to support new drug development investigations on the International Space Station (ISS) using Redwire’s Pharmaceutical In-space Laboratory (PIL-BOX) technology.
This additional funding expands an existing task order under a $25 million, five-year indefinite-delivery/indefinite-quantity contract through NASA’s In Space Production Applications (InSPA) program.
With 43 units flown, PIL-BOX has contributed to the growth of high‑quality crystals that could transform how lifesaving medicines are developed. Redwire recently supported a cancer therapy investigation led by Aspera Biomedicines (Aspera) that launched aboard the SpaceX Crew-12 mission to the ISS.
Aspera and Redwire are using PIL‑BOX to advance development of rebecsinib, an ADAR1 inhibitor. Results from the investigation have the potential to enable new drug formulations that will provide broader cancer treatment options, the company said.

More on Redwire